Novo Nordisk’s Double-Edged Week: A Ransomware Demand and a Pill Prescription Blitz
20.06.2026 - 10:01:28 | boerse-global.de
The Copenhagen-based drugmaker ended the week with its shares trading at €38.90, having climbed roughly 3% on Friday alone. That rebound came despite the disclosure that hackers had exfiltrated a trove of sensitive corporate files, including internal drug dossiers and clinical trial data. The group behind the attack, FulcrumSec, demanded a $25 million ransom; Novo Nordisk refused to pay. Investors, however, appeared to view the operational tailwinds as far more compelling than the cybersecurity lapse.
The real catalyst came from the oral version of Wegovy. Since its US launch in January, the tablet has racked up more than 3 million prescriptions, with two million of those written by the end of the first quarter alone. Crucially, roughly 80% of patients using the pill had never before taken a GLP-1 therapy. That statistic suggests the oral formulation is expanding the addressable market rather than merely cannibalising sales of the injectable product. The strong take-up has nudged management to lift the full-year guidance modestly, driven by better-than-expected demand across the GLP-1 portfolio.
Nordea recently upgraded the stock from “Hold” to “Buy”, a vote of confidence that helped stem the bleeding after a 40% rout over the past twelve months. The shares had plunged from a 52-week high of €65.20 to a low of €30.25 in March, and the current price still sits nearly 29% above that trough. The move back above the 50-day moving average of €36.99 signals a shift in near-term momentum, though the 200-day line at €41.16 remains the next major hurdle on the path to a sustained recovery.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Attention is now turning to CagriSema, the next-generation obesity candidate that is under FDA review for approval this year. In the REDEFINE-1 study, nearly 92% of patients lost at least 5% of their body weight. Still, a head-to-head comparison with Eli Lilly’s Zepbound showed inferior weight-loss outcomes, underscoring the competitive pressure Novo Nordisk faces. The pipeline also suffered a blow earlier this year when the new chief executive culled several drug programmes and slashed 9,000 jobs, targeting annual savings of 8 billion Danish kroner by 2026. The restructuring is painful but necessary, the company argues, as it pivots resources toward the highest-growth opportunities.
Longer-term, the cloud from the data breach may yet darken. FulcrumSec has already published some of the stolen materials, raising the risk of intellectual property leakage or regulatory backlash. Deutsche Bank, meanwhile, warns of a “patent cliff” looming in 2031, when roughly $30 billion in revenue could come under threat. Closer to home, the Chinese patent on semaglutide expired earlier this spring, opening the door for generics. Novo Nordisk is racing to secure an oral Wegovy approval in China, where it currently holds a 65% market share among new obesity prescriptions.
For now, the recovery story is built on solid fundamentals. The stock trades at a forward price-to-earnings multiple of 13, a steep discount to the healthcare sector average of over 17. That gap reflects genuine concerns but also, many believe, an overdose of pessimism. With a dividend yield of roughly 4% and an installed base of 26 million insulin patients plus 15 million GLP-1 diabetes users, the company’s core business remains formidable.
Friday’s advance showed that the market is willing to look past the ransomware incident as long as the product engine keeps firing. Whether the shares can climb back to pre-crash levels will depend on how well Novo Nordisk sustains its oral Wegovy momentum, navigates the competitive landscape, and manages the patent expirations ahead. The road to recovery appears likely to be gradual rather than explosive, but the direction has clearly improved.
Ad
Novo Nordisk Stock: New Analysis - 20 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
